Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-Related death in allogeneic marrow transplant recipients: Long-Term follow-up of a randomized, placebo-controlled trial

Blood

Volumn 96, Issue 6, 2000, Pages 2055-2061

  Marr, Kieren A ^a,b   Seidel, Kristy ^a   Slavin, Monica A ^a   Bowden, Raleigh A ^a   Gary Schoch, H ^a   Flowers, Mary E D ^a   Corey, Lawrence ^a   Boeckh, Michael ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; FLUCONAZOLE; METHOTREXATE; PLACEBO;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANDIDIASIS; CAUSE OF DEATH; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; INCIDENCE; INFECTION PREVENTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 0034665657     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.6.2055     Document Type: Article

References (24)

1. Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: Final results and long-term follow-up of an open-label prospective randomized trial
2. Effect of high-dose acyclovir on survival in allogeneic marrow transplant recipients who received ganciclovir at engraftment or for cytomegalovirus pp65 antigenemia
3. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantalion: A randomized double-blind study
4. Fungal infections in patients undergoing bone marrow transplantation: An approach to a rational management protocol
5. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation
6. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation
7. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation
8. Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia
9. Antifungal prophylaxis to prevent invasive mycoses among bone marrow transplant recipients
10. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia
11. Mortality and gross pathology of secondary disease in germ-free mouse radiation chimeras
12. Antifungal prophylaxis during neutropenia and immunodeficiency
13. Candidemia in allogeneic blood and marrow transplant recipients: Evolution of risk factors after the adoption of prophylactic fluconazole
14. Fungal infections in bone marrow transplant patients
15. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation
16. Consensus conference on acute GVHD grading
17. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: Benefit based on purpose and intensity of cytotoxic therapy
18. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study
19. Long-term survival and late deaths after allogeneic bone marrow transplantation: Late Effects Working Committee of the International Bone Marrow Transplant Registry
20. Chronic graft-versus-host disease and other late complications of bone marrow transplantation
21. Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora
22. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis
23. Clinical, cellular and molecular factors that contribute to antifungal drug resistance
24. Importance of Candida species other than C. albicans as pathogens in oncology patients